The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

OBJECTIVE: In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucos...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Oelze, Matthias, Kröller-Schön, Swenja, Welschof, Philipp, Jansen, Thomas, Hausding, Michael, Mikhed, Yuliya, Stamm, Paul, Mader, Michael, Zinßius, Elena, Agdauletova, Saule, Gottschlich, Anna, Steven, Sebastian, Schulz, Eberhard, Bottari, Serge P., Mayoux, Eric, Münzel, Thomas, Daiber, Andreas
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4234367/
https://ncbi.nlm.nih.gov/pubmed/25402275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0112394
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires